

## Press Release

# Bilcare GCS Expands Phase III Clinical Trial Service Capabilities

SAN FRANCISCO — September 4, 2008 — As part of its commitment to providing its customers with comprehensive services that span the entire clinical supply chain, Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial supplies and services, has enhanced its global Phase III capabilities. Its latest Phase III investments include the upgrade of its Kalish large-scale bottling line at its U.S. facility and an investment in new Pentapack blistering technology for expanded packaging capabilities in America and Europe.

“Our experiences over the past few years, along with those of our customers, have shown us that the pharmaceutical industry has tired of working with multiple partners during different clinical trial phases,” said Vito Mangiardi, chief executive officer of Bilcare GCS. “The management of numerous partners is cumbersome, and working with varying levels of R&D, quality control, and project and delivery turnaround times can skew a trial’s timeline. By investing in large-scale equipment technology, we’re offering our customers what no other partner can: a true, integrated partnership that can take them from beginning-phase research and development through Phase III.”

Bilcare GCS’ investment in the Pentapack CT1200L system allows the company to package high-volume runs for large-scale clinical trials and stability tests. This latest technology gives Bilcare GCS additional flexibility in trial design and execution to meet individual client needs.

The Pentapack system enables Bilcare GCS to design blister packaging configurations online using Trialpack Designer II packaging design software, and immediately implement them for production. The machine can produce thermoformed and cold-formed blisters from a variety of materials and features multi-product flood feeding. The vision system checks the content of blisters and verifies accurate product placement before sealing. A programmable cutting station provides the flexibility to meet specific customer demands and match all pharmaceutical standards. The system’s automation significantly reduces manufacturing times and creates a 21 CFR Part 11-compliant electronic paper trail that documents changes from design to production through quality control.

“Bilcare GCS has built its reputation on providing customers with the highest quality research services and clinical supplies delivered on time, every time,” said Vince Santa Maria, president of Bilcare GCS, Americas. “The Pentapack and the expanded Kalish lines are key components to taking Bilcare’s Phase III clinical trial services to the next level by leveraging state-of-the art packaging technologies to deliver superior quality products in a highly flexible and efficient manner. These latest investments are further proof of Bilcare’s long-term commitment to serving the industry with exceptional quality and service beyond compliance.”

## About Bilcare Global Clinical Supplies

Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services, and complete project management. Its services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements; from pre-formulation research and development, manufacturing, analytical services and clinical supplies packaging and labeling, to IVRS, QP services, controlled temperature (cold chain) CTM storage, distribution worldwide, and returns and destructions accountability.

For more information about Bilcare Global Clinical Supplies, visit [www.bilcaregcs.com](http://www.bilcaregcs.com) .

### Media Contact

Deborah Buscarino  
Director, Marketing & Communications  
Phone: 610-422-3204  
Deborah.Buscarino@bilcare.com

Bilcare Research  
Tel: +91 20 30257700  
Email: [corpcomm@bilcare.com](mailto:corpcomm@bilcare.com)